These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

305 related articles for article (PubMed ID: 31111762)

  • 1. The National MDS Natural History Study: design of an integrated data and sample biorepository to promote research studies in myelodysplastic syndromes.
    Sekeres MA; Gore SD; Stablein DM; DiFronzo N; Abel GA; DeZern AE; Troy JD; Rollison DE; Thomas JW; Waclawiw MA; Liu JJ; Al Baghdadi T; Walter MJ; Bejar R; Gorak EJ; Starczynowski DT; Foran JM; Cerhan JR; Moscinski LC; Komrokji RS; Deeg HJ; Epling-Burnette PK
    Leuk Lymphoma; 2019 Dec; 60(13):3161-3171. PubMed ID: 31111762
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Connect MDS/AML: design of the myelodysplastic syndromes and acute myeloid leukemia disease registry, a prospective observational cohort study.
    Steensma DP; Abedi M; Bejar R; Cogle CR; Foucar K; Garcia-Manero G; George TI; Grinblatt D; Komrokji R; Ma X; Maciejewski J; Pollyea DA; Savona MR; Scott B; Sekeres MA; Thompson MA; Swern AS; Nifenecker M; Sugrue MM; Erba H
    BMC Cancer; 2016 Aug; 16():652. PubMed ID: 27538433
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Health-related quality of life and vulnerability among people with myelodysplastic syndromes: a US national study.
    Abel GA; Hebert D; Lee C; Rollison D; Gillis N; Komrokji R; Foran JM; Liu JJ; Al Baghdadi T; Deeg J; Gore S; Saber W; Wilson S; Otterstatter M; Thompson J; Borchert C; Padron E; DeZern A; Cella D; Sekeres MA
    Blood Adv; 2023 Jul; 7(14):3506-3515. PubMed ID: 37146263
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Genomic aberrations of myeloproliferative and myelodysplastic/myeloproliferative neoplasms in chronic phase and during disease progression.
    Hahm C; Huh HJ; Mun YC; Seong CM; Chung WS; Huh J
    Int J Lab Hematol; 2015 Apr; 37(2):181-9. PubMed ID: 24845343
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Distribution of cytogenetic abnormalities in myelodysplastic syndromes, Philadelphia negative myeloproliferative neoplasms, and the overlap MDS/MPN category.
    Bacher U; Schnittger S; Kern W; Weiss T; Haferlach T; Haferlach C
    Ann Hematol; 2009 Dec; 88(12):1207-13. PubMed ID: 19415278
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Discordant pathologic diagnoses of myelodysplastic neoplasms and their implications for registries and therapies.
    Gorak EJ; Otterstatter M; Al Baghdadi T; Gillis N; Foran JM; Liu JJ; Bejar R; Gore SD; Kroft SH; Harrington A; Saber W; Starczynowski D; Rollison DE; Zhang L; Moscinski L; Wilson S; Thompson J; Borchert C; Sherman S; Hebert D; Walker ME; Padron E; DeZern AE; Sekeres MA
    Blood Adv; 2023 Oct; 7(20):6120-6129. PubMed ID: 37552083
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Progression, transformation, and unusual manifestations of myelodysplastic syndromes and myelodysplastic-myeloproliferative neoplasms: lessons learned from the XIV European Bone Marrow Working Group Course 2019.
    Hebeda K; Boudova L; Beham-Schmid C; Orazi A; Kvasnicka HM; Gianelli U; Tzankov A
    Ann Hematol; 2021 Jan; 100(1):117-133. PubMed ID: 33128619
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Genomic aberrations in myelodysplastic syndromes and related disorders].
    Makishima H
    Rinsho Ketsueki; 2019; 60(6):600-609. PubMed ID: 31281151
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Making sense of the myelodysplastic/myeloproliferative neoplasms overlap syndromes.
    Tiu RV; Sekeres MA
    Curr Opin Hematol; 2014 Mar; 21(2):131-40. PubMed ID: 24378705
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Challenges in Diagnosing Myelodysplastic Syndromes in the Era of Genetic Testing: Proceedings of the 13th Workshop of the European Bone Marrow Working Group.
    Hebeda KM; Tzankov A; Boudova L; Saft L; Hasserjian RP; de Boer M; Fend F; Orazi A; Leguit R
    Pathobiology; 2019; 86(1):62-75. PubMed ID: 29982244
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of chromosome alterations, genetic mutations and clonal hematopoiesis of indeterminate potential (CHIP) on the classification and risk stratification of MDS.
    Ganguly BB; Banerjee D; Agarwal MB
    Blood Cells Mol Dis; 2018 Mar; 69():90-100. PubMed ID: 29079134
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lymphoblastic leukemia following myelodysplastic syndromes or myelodysplastic/myeloproliferative neoplasms.
    Xie W; Chen Z; Wang SA; Hu S; Li S; Miranda RN; Medeiros LJ; Tang G
    Leuk Lymphoma; 2019 Dec; 60(12):2993-3001. PubMed ID: 31017498
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Distinguishing myelodysplastic syndromes (MDS) from idiopathic cytopenia of undetermined significance (ICUS): HUMARA unravels clonality in a subgroup of patients.
    Schroeder T; Ruf L; Bernhardt A; Hildebrandt B; Aivado M; Aul C; Gattermann N; Haas R; Germing U
    Ann Oncol; 2010 Nov; 21(11):2267-2271. PubMed ID: 20439346
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Unique ethnic features of
    Choi EJ; Cho YU; Hur EH; Jang S; Kim N; Park HS; Lee JH; Lee KH; Kim SH; Hwang SH; Seo EJ; Park CJ; Lee JH
    Haematologica; 2022 Feb; 107(2):510-518. PubMed ID: 33626862
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Cytogenetic characteristics of hematopoietic and stromal progenitor cells in myelodysplastic syndrome].
    Pimenova MA; Parovichnikova EN; Kokhno AV; Domracheva EV; Manakova TE; Mal'tseva IuS; Konnova ML; Shishigina LA; Savchenko VG
    Ter Arkh; 2013; 85(7):34-42. PubMed ID: 24137945
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Myelodysplastic syndromes in children.
    Galaverna F; Ruggeri A; Locatelli F
    Curr Opin Oncol; 2018 Nov; 30(6):402-408. PubMed ID: 30222640
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeted Next-Generation Sequencing in Myelodysplastic Syndrome and Chronic Myelomonocytic Leukemia Aids Diagnosis in Challenging Cases and Identifies Frequent Spliceosome Mutations in Transformed Acute Myeloid Leukemia.
    Reinig E; Yang F; Traer E; Arora R; Brown S; Rattray R; Braziel R; Fan G; Press R; Dunlap J
    Am J Clin Pathol; 2016 Apr; 145(4):497-506. PubMed ID: 27124934
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Defining the Boundary Between Myelodysplastic Syndromes and Myeloproliferative Neoplasms.
    Loghavi S; Wang SA
    Surg Pathol Clin; 2019 Sep; 12(3):651-669. PubMed ID: 31352979
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Sequential acquisition of mutations in myelodysplastic syndromes].
    Makishima H
    Rinsho Ketsueki; 2017; 58(10):1828-1837. PubMed ID: 28978821
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inherited thrombocytopenia and platelet disorders with germline predisposition to myeloid neoplasia.
    Galera P; Dulau-Florea A; Calvo KR
    Int J Lab Hematol; 2019 May; 41 Suppl 1():131-141. PubMed ID: 31069978
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.